ImmunityBio Inc. (NASDAQ:IBRX) shares traded -13.00% lower at $2.81 on Wall Street last session.
In accordance with the data, 2 analysts cover ImmunityBio Inc. (NASDAQ:IBRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $4.00, we find $4.50. Given the previous closing price of $3.23, this indicates a potential upside of 39.32 percent. IBRX stock price is now 16.89% away from the 50-day moving average and -32.35% away from the 200-day moving average. The market capitalization of the company currently stands at $1.50B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
It has been rated a hold by 1 analysts and a buy by 1. Brokers who have rated the stock have averaged $4.50 as their price target over the next twelve months.
With the price target reduced from $10 to $4, Piper Sandler Downgraded its rating from Overweight to Neutral for ImmunityBio Inc. (NASDAQ: IBRX). On August 03, 2022, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $8.
Insiders disposed of 46,465 shares of company stock worth roughly $0.13 million over the past 1 year. A total of 72.71% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IBRX stock. A new stake in ImmunityBio Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $16,287,000. TANG CAPITAL MANAGEMENT LLC invested $3,079,000 in shares of IBRX during the first quarter. In the first quarter, MILLENNIUM MANAGEMENT LLC acquired a new stake in ImmunityBio Inc. valued at approximately $1,464,000. SQUAREPOINT OPS LLC acquired a new stake in IBRX for approximately $1,354,000. OCCUDO QUANTITATIVE STRATEGIES LP purchased a new stake in IBRX valued at around $1,121,000 in the second quarter. In total, there are 211 active investors with 10.30% ownership of the company’s stock.
ImmunityBio Inc. (NASDAQ: IBRX) opened at $3.1500 on Thursday. During the past 12 months, ImmunityBio Inc. has had a low of $1.21 and a high of $7.80. As of last week, the company has a debt-to-equity ratio of 1.31, a current ratio of 0.20, and a quick ratio of 0.20. The fifty day moving average price for IBRX is $2.4278 and a two-hundred day moving average price translates $4.1494 for the stock.
The latest earnings results from ImmunityBio Inc. (NASDAQ: IBRX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.27, missing analysts’ expectations of -$0.22 by -0.05. This compares to -$0.26 EPS in the same period last year. The company reported revenue of $0.36 million for the quarter, compared to $14000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2471.43 percent. For the current quarter, analysts expect IBRX to generate $360k in revenue.
ImmunityBio Inc.(IBRX) Company Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
